Search

Search Constraints

You searched for: Author/Creator Postema, R

Search Results

1. LBA18_PRDurable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). (23rd October 2018)

3. AB0397 Abatacept shows better sustainability than tnf inhibitors when used following initial biologic dmard failure in the treatment of rheumatoid arthritis: 8 years of real-world observations from the rhumadata® clinical database and registry. (15th June 2017)

5. FRI0230 Retention rates of tnf inhibitors and abatacept used as a first biologic dmard in the treatment of rheumatoid arthritis: 8 years of experience from the rhumadata® registry. (15th June 2017)